Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
| Autor: | Martin, M., Zielinski, C., Ruiz-Borrego, M., Carrasco, E., Turner, N., Ciruelos, E.M., Muñoz, M., Bermejo, B., Margeli, M., Anton, A., Kahan, Z., Csöszi, T., Casas, M.I., Murillo, L., Morales, S., Alba, E., Gal-Yam, E., Guerrero-Zotano, A., Calvo, L., de la Haba-Rodriguez, J., Ramos, M., Alvarez, I., Garcia-Palomo, A., Huang Bartlett, C., Koehler, M., Caballero, R., Corsaro, M., Huang, X., Garcia-Sáenz, J.A., Chacón, J.I., Swift, C., Thallinger, C., Gil-Gil, M. |
|---|---|
| Zdroj: | In Annals of Oncology April 2021 32(4):488-499 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|